Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteafraxis.com
Phone858-750-4707
Employees

Offices

La Jolla, USA
11099 N Torrey Pines Rd, Suite 290
La Jolla, CA, 92037
USA

People

Chief Executive Officer
Chief Scientific Officer

Funding

TOTAL $1.2M
FUNDING TOTAL $1.2M
Partial Close, 5/2010
$1.2M
DEBT TOTAL $300k
Debt, 12/2011
$300k

Tags

Afraxis

Afraxis is discovering and developing drugs to treat diseases of the central nervous system, including schizophrenia, Alzheimer’s disease, Fragile X syndrome and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines. Afraxis is leveraging this discovery to develop drug treatments that control dendritic spine function. The company’s lead program targets PAK, a protein that regulates the development and activity of dendritic spines, creating therapies that actually modify the disease rather than just treat symptoms. Modifying the disease produces beneficial changes at the cellular and behavioral level, creating new hope for patients.

Recent Milestones

Videos

Screenshots

Sources

  1. SEC (sec.gov) [edit]
  2. SEC (sec.gov) [edit]
Edit This Page
Last Edited 12/19/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy